Fri, 26 Feb 2021 13:39:41: | Artiva, fresh from Merck pact, raises $120M for NK therapy R&D
|
Fri, 26 Feb 2021 12:51:29: | Genentech teams with academics for 10-year neuroscience R&D push
|
Fri, 26 Feb 2021 12:30:34: | Oncolytics Bio's cancer-killing virus arms CAR-T cells to attack solid tumors in mice
|
Fri, 26 Feb 2021 12:18:27: | Chutes & Ladders—Moderna CMO hits exit amid COVID-19 vaccine rollout
|
Fri, 26 Feb 2021 08:47:07: | FDA tells Merck to show more data for its OncoImmune COVID-19 drug as EUA pushed back
|
Fri, 26 Feb 2021 08:14:08: | Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'
|
Thu, 25 Feb 2021 13:36:03: | Merck inks $1.9B Pandion takeover to square up against Amgen, Lilly and Roche
|
Thu, 25 Feb 2021 13:25:55: | Overcoming chemotherapy resistance in leukemia with a diarrhea drug from Merck
|
Thu, 25 Feb 2021 12:24:46: | Moderna's CMO Zaks quits for 'next leg of his career' after swift move to commercial focus
|
Thu, 25 Feb 2021 09:21:46: | GSK fails COVID-19 phase 2, subgroup finding fuels further work
|
Wed, 24 Feb 2021 13:23:49: | UCB taps Microsoft to accelerate drug discovery, clinical trials
|
Wed, 24 Feb 2021 12:49:07: | Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
|
Wed, 24 Feb 2021 11:48:39: | Insights into how coronavirus changes shape could aid development of COVID-19 vaccines, drugs
|
Wed, 24 Feb 2021 11:23:28: | The CRO megamerger is back as Icon snaps up PRA Health for $12B
|
Wed, 24 Feb 2021 10:43:36: | Sanofi, following Denali, pens gene therapy pact with Sirion Biotech
|
Tue, 23 Feb 2021 13:50:18: | Merck KGaA offloads clinical-phase cancer drugs to Day One
|
Tue, 23 Feb 2021 13:13:13: | Clover raises $230M as COVID-19 vaccine nears phase 3, multivariant prospect gets going
|
Tue, 23 Feb 2021 08:52:44: | Intercept loses chief medical officer months after CEO stepped down
|
Mon, 22 Feb 2021 14:24:21: | Genmab creates new CMO, head of experimental medicines role for Ahmadi
|
Mon, 22 Feb 2021 14:07:39: | Amping up the immune system's T cells to improve their cancer-killing prowess
|
Mon, 22 Feb 2021 13:34:29: | Otonomy fails phase 3, adding another twist to ear disease saga
|
Mon, 22 Feb 2021 11:53:49: | After setback, Sanofi, GSK take tweaked COVID-19 vaccine into phase 2
|
Mon, 22 Feb 2021 09:42:59: | Daiichi Sankyo poaches Kite's research lead Takeshita from parent Gilead
|
Fri, 19 Feb 2021 14:44:55: | Precision's one-time gene editing treatment lowers cholesterol in monkeys for 3 years
|
Fri, 19 Feb 2021 13:27:10: | As J&J eyes approval for its one-shot COVID-19 vax, it sends off phase 3 data for a swift WHO listing
|